These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
329 related items for PubMed ID: 3054909
1. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen. Sternberg CN, Yagoda A, Scher HI. Prog Clin Biol Res; 1988; 277():45-51. PubMed ID: 3054909 [No Abstract] [Full Text] [Related]
2. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma. Balbay MD, Ozen H, Uluçay S, Sahin A, Ergen A, Koçal C, Remzi D. Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565 [Abstract] [Full Text] [Related]
4. Neo-adjuvant M-VAC chemotherapy trials in transitional cell carcinoma: perspectives for first line chemotherapy. Sternberg CN, Yagoda A, Scher HI, Whitmore WF, Herr HW, Morse MJ, Sogani PC, Bosl G, Watson RC, Hollander PS. Prog Clin Biol Res; 1988 Feb; 260():551-5. PubMed ID: 3283770 [No Abstract] [Full Text] [Related]
5. Extended experience of neo-adjuvant M-VAC chemotherapy for T1-4 N0 M0 transitional cell carcinoma of the urinary bladder. Keating JP, Zincke H, Hahn RG, Morgan WR. Prog Clin Biol Res; 1990 Feb; 353():119-27. PubMed ID: 2217409 [No Abstract] [Full Text] [Related]
6. [The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder]. Stöckle M, Meyenburg W, Wellek S, Voges G, Gertenbach U, Thüroff JW, Huber C, Hohenfellner R. Ann Urol (Paris); 1993 Feb; 27(1):51-7. PubMed ID: 7682388 [Abstract] [Full Text] [Related]
7. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report. Gohji K, Higuchi A, Maruyama S, Minayoshi K, Fujii A, Itoh N, Hasunuma Y, Tanaka H, Izumi T. Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990 [Abstract] [Full Text] [Related]
8. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer]. Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O. Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405 [Abstract] [Full Text] [Related]
9. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC]. Seguchi T, Nakano E, Miki T, Kondoh M, Nishimura K, Nakamura N, Okuyama A. Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917 [Abstract] [Full Text] [Related]
10. Possible alternative treatment for advanced transitional cell carcinoma of the urothelium (N+ and/or M+) in 1988. Perrin P, Mouriquand P, Monsallier M, Devonec M. Prog Clin Biol Res; 1989 Jan; 303():617-9. PubMed ID: 2780666 [No Abstract] [Full Text] [Related]
11. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium. Sternberg CN, Yagoda A, Scher HI, Whitmore WF, Herr HW, Morse MJ, Sogani PC, Watson RC, Hollander PS, Fair WR. Prog Clin Biol Res; 1988 Jan; 260():481-5. PubMed ID: 3283768 [No Abstract] [Full Text] [Related]
12. [Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) chemotherapy for advanced urothelial cancers]. Takenaka A, Gotoh A, Hara I, Gohji K, Ogawa T, Arakawa S, Matsumoto O, Kamidono S, Hamami G, Itani A. Gan To Kagaku Ryoho; 1990 Sep; 17(9):1909-15. PubMed ID: 2393308 [Abstract] [Full Text] [Related]
13. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract. Koch MO, Coussens D. Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122 [No Abstract] [Full Text] [Related]
14. [M-VAC chemotherapy for patients with lymph node metastases and/or locally advanced bladder carcinoma]. Igawa M, Ueki T, Ueda M, Okada K, Usui T, Ohnishi Y, Nakatsu H, Kume T, Kodama M, Masu C. Hinyokika Kiyo; 1989 Aug; 35(8):1323-7. PubMed ID: 2683648 [Abstract] [Full Text] [Related]
15. Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status. Walther PJ. Semin Urol; 1993 Nov; 11(4):227-34. PubMed ID: 8290828 [No Abstract] [Full Text] [Related]
16. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G. Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851 [Abstract] [Full Text] [Related]
19. [Complete remission of brain metastasis of bladder cancer treated by M-VAC therapy]. Nakagawa S, Nakao M, Toyoda K, Nukui M, Takada H, Ebisui K. Hinyokika Kiyo; 1989 Feb 15; 35(2):333-5. PubMed ID: 2735244 [Abstract] [Full Text] [Related]
20. [Combination chemotherapy of methotrexate, etoposide, adriamycin and cisplatin (M-EAP) for advanced urothelial cancer]. Hashimura T, Okumura K, Akao T, Nakagawa T. Hinyokika Kiyo; 1991 Jul 15; 37(7):685-8. PubMed ID: 1927767 [Abstract] [Full Text] [Related] Page: [Next] [New Search]